Prevention of cardiotoxicity among survivors of childhood cancer

Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco, Steven E. Lipshultz

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Linked Articles: This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381. The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.

Original languageEnglish (US)
Pages (from-to)455-465
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Volume83
Issue number3
DOIs
StatePublished - 2017

Keywords

  • cardiotoxicity
  • childhood cancer
  • dexrazoxane
  • survivor

Fingerprint Dive into the research topics of 'Prevention of cardiotoxicity among survivors of childhood cancer'. Together they form a unique fingerprint.

Cite this